The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Clinical actionability of molecular targets in endometrial cancer
Open accessAbstract
Endometrial cancer accounts for ~76,000 deaths among women each year worldwide. Disease mortality and the increasing number of new diagnoses make endometrial cancer an important consideration in women's health, particularly in industrialized countries, where the incidence of this tumour type is highest. Most endometrial cancers are carcinomas, with the remainder being sarcomas. Endometrial carcinomas can be classified into several histological subtypes, including endometrioid, serous and clear cell carcinomas. Histological subtyping is currently used routinely to guide prognosis and treatment decisions for endometrial cancer patients, while ongoing studies are evaluating the potential clinical utility of molecular subtyping. In this Review, we summarize the overarching molecular features of endometrial cancers and highlight recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the combined presence of PTEN and PIK3CA or PIK3R1 mutations are frequently observed suggesting that both loss of tumor suppressor and activation of oncogenes is required during tumor progression53.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Yang, W., Lum, A. M., Senz, J., Boyd, N., Pike, J. A., Anglesio, M. S., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 1,007
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 989
Stelloo, E., Nout, R. A., Osse, E. M., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 856
Cited by
Sorted by citations
The potential role of RNA N6-methyladenosine in Cancer progression
Wang, T., Kong, S., Tao, M., & Ju, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01204-7 · Cited by 1,044
Makker, V., MacKay, H. J., Ray-Coquard, I. L., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 734
Lu, Q., Zhu, Y., Deng, C., Liang, Z., Chen, J., Chen, Y., Wang, X., Liu, Y., Tian, Y., & Yang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01756-w · Cited by 391
The RING finger protein family in health and disease
Cai, C., Tang, Y., Zhai, J., & Zheng, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01152-2 · Cited by 204
Progesterone Actions and Resistance in Gynecological Disorders
MacLean, J. A., & Hayashi, K. (2022) · Cells · doi:10.3390/cells11040647 · Cited by 199
Matsuzaki, S., Klar, M., Matsuzaki, S., Roman, L. D., Sood, A. K., & Matsuo, K. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.043 · Cited by 120
Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives
Terzić, M., Aimagambetova, G. N., Kunz, J., Bapayeva, G., Aitbayeva, B., Terzic, S., & Laganà, A. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179274 · Cited by 115
Zhou, W., Zhang, J., Xie, F., Wu, J., Ye, J., Wang, J., Wu, K., & Li, M. (2021) · Theranostics · doi:10.7150/thno.58337 · Cited by 107
Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection
Galant, N., Krawczyk, P. A., Monist, M. J., Obara, A., Gajek, Ł., Grenda, A., Nicoś, M., Kalinka‐Warzocha, E., & Milanowski, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115893 · Cited by 117
Genomic landscape of endometrial carcinomas of no specific molecular profile
Boroujeni, A. M., Nguyen, B., Vanderbilt, C., Ladanyi, M., Abu‐Rustum, N. R., Aghajanian, C. A., Ellenson, L. H., Weigelt, B., & Soslow, R. A. (2022) · Modern Pathology · doi:10.1038/s41379-022-01066-y · Cited by 98
Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers
Chimento, A., Luca, A. D., Avena, P., Amicis, F. D., Casaburi, I., Sirianni, R., & Pezzi, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031242 · Cited by 98
Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies
Yang, Y., Wu, S. F., & Bao, W. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14969 · Cited by 96
Gu, X., Shi, Y., Dong, M., Li, J., Yang, J., & Liu, Z. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04087-8 · Cited by 82
Current and Emerging Prognostic Biomarkers in Endometrial Cancer
Njoku, K., Barr, C. E., & Crosbie, E. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.890908 · Cited by 87
Recurrent Endometrial Cancer: Local and Systemic Treatment Options
Rütten, H., Verhoef, C. G., van Weelden, W. J., Smits, A., Dhanis, J., Ottevanger, N. P. B., & Pijnenborg, J. M. A. (2021) · Cancers · doi:10.3390/cancers13246275 · Cited by 81
Minimally invasive approaches for the early detection of endometrial cancer
Shen, Y., Yang, W., Liu, J., & Zhang, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01757-3 · Cited by 76
Current Approaches to the Management of Patients with Endometrial Cancer
Kalampokas, E., Giannis, G., Kalampokas, T., Papathanasiou, A.-A., Mitsopoulou, D., Tsironi, E. E., Triantafyllidou, O., Gurumurthy, M., Parkin, D. E., Cairns, M. R., et al. (2022) · Cancers · doi:10.3390/cancers14184500 · Cited by 74
Gullo, G., Etrusco, A., Cucinella, G., Perino, A., Chiàntera, V., Laganà, A. S., Tomaiuolo, R., Vitagliano, A., Giampaolino, P., Noventa, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111825 · Cited by 70
One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids
Geurts, M. H., Gandhi, S., Boretto, M. G., Akkerman, N., Derks, L. L. M., van Son, G., Celotti, M., Harshuk-Shabso, S., Peci, F., Begthel, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40701-3 · Cited by 66
Wang, Y., Wang, C., Guan, X., Ma, Y., Zhang, S., Li, F., Yin, Y., Sun, Z., Chen, X., & Yin, H. (2023) · Advanced Science · doi:10.1002/advs.202303812 · Cited by 67
The Significance of Secreted Phosphoprotein 1 in Multiple Human Cancers
Wei, T., Bi, G., Bian, Y., Ruan, S., Yuan, G., Xie, H., Zhao, M., Shen, R., Zhu, Y., Wang, Q., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.565383 · Cited by 65
High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential
Wang, L., Zhang, J., Xia, M. H., Liu, C., Zu, X., & Zhong, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72952 · Cited by 63
Abdelmaksoud, N. M., El‐Mahdy, H. A., Ismail, A., Elsakka, E. G. E., El-Husseiny, A. A., Khidr, E. G., Ali, E. M., Rashed, M. H., El-Demerdash, F. E.-S., & Doghish, A. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154411 · Cited by 63
Yasin, H. K., Taylor, A. H., & Ayakannu, T. (2021) · Cancers · doi:10.3390/cancers13092149 · Cited by 65
Liang, C., Zhang, X., Yang, M., Wang, W., Chen, P., & Dong, X. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00259 · Cited by 60
LncRNA–miRNA–mRNA regulatory axes in endometrial cancer: a comprehensive overview
Shetty, A., Venkatesh, T., Kabekkodu, S. P., Tsutsumi, R., & Suresh, P. S. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06423-5 · Cited by 60
Jiang, R., Su, G., Chen, X., Chen, S., Li, Q., Xie, B., & Zhao, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.039 · Cited by 60
The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
Pang, Y., Bai, G., Zhao, J., Wei, X., Li, R., Li, J., Hu, S., Peng, L., Liu, P., & Mao, H. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03545-x · Cited by 59
Lin, Z., Sui, X., Jiao, W., Chen, C., Zhang, X., & Zhao, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.953874 · Cited by 57
Facts and Hopes in Immunotherapy of Endometrial Cancer
Marín‐Jiménez, J. A., García‐Mulero, S., Matías‐Guiu, X., & Piulats, J. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1564 · Cited by 54
Metabolic reprogramming and interventions in endometrial carcinoma
Li, J., Yang, H., Zhang, L., Zhang, S., & Dai, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114526 · Cited by 54
Regulatory mechanism of miR-20a-5p expression in Cancer
Huang, W., Wu, X., Xiang, S., Qiao, M., Cen, X. B., Pan, X., Huang, X., & Zhao, Z. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01005-5 · Cited by 53
Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer
Kojima, M., Sugimoto, K., Tanaka, M., Endo, Y., Kato, H., Honda, T., Furukawa, S., Nishiyama, H., Watanabe, T., Soeda, S., et al. (2020) · Cancers · doi:10.3390/cancers12102748 · Cited by 51
Tissue Infiltrating Immune Cells as Prognostic Biomarkers in Endometrial Cancer: A Meta-Analysis
Guo, F., Dong, Y., Tan, Q., Kong, J., & Yu, B. (2020) · Disease Markers · doi:10.1155/2020/1805764 · Cited by 49
WTAP facilitates progression of endometrial cancer via CAV‐1/NF‐κB axis
Li, Q., Wang, C., Dong, W., Su, Y., & Ma, Z. (2021) · Cell Biology International · doi:10.1002/cbin.11570 · Cited by 48
Hsin, I., Shen, H., Chang, H. H., Ko, J., & Wang, P.-H. (2021) · Cells · doi:10.3390/cells10112916 · Cited by 50
Dai, M., Yang, B., Chen, J., Liu, F., Zhou, Y., Zhou, Y., Xu, Q., Jiang, S., Zhao, S., Li, X., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.024 · Cited by 49
Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis
Reske, J. J., Wilson, M. R., Holladay, J., Siwicki, R. A., Skalski, H. J., Harkins, S. K., Adams, M., Risinger, J. I., Hostetter, G. H., Lin, K. Y., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009986 · Cited by 45
Lin, Z., Sui, X., Jiao, W., Wang, Y., & Zhao, J. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03623-z · Cited by 42
Autophagy Machinery as a Promising Therapeutic Target in Endometrial Cancer
Núñez-Olvera, S. I., Gallardo‐Rincón, D., Puente-Rivera, J., Salinas-Vera, Y. M., Marchat, L. A., Morales-Villegas, R., & López‐Camarillo, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01326 · Cited by 41
Kojima, M., Sugimoto, K., Kobayashi, M., Ichikawa‐Tomikawa, N., Kashiwagi, K., Watanabe, T., Soeda, S., Fujimori, K., Chiba, H., Nishiyama, H., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0835 · Cited by 39
Zhan, L., Zhang, J., Zhang, J., Liu, X., Zhu, S., Shi, Y., He, Y., Wang, W., Fan, Y., Tang, Z., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.031 · Cited by 40
Lv, M., Chen, P., Bai, M., Huang, Y., Li, L., Feng, Y., Liao, H., Zheng, W., Chen, X., & Zhang, Z. (2022) · Cancers · doi:10.3390/cancers14246210 · Cited by 45
Organoid Models of Human Endometrial Development and Disease
Hibaoui, Y., & Féki, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00084 · Cited by 40
Ren, F., Wang, L., Wang, Y., Wang, J., Wang, Y., Song, X., Zhang, G., Nie, F., & Lin, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06960-8 · Cited by 46
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer
Tang, W., Ramasamy, K., Pillai, S. M. A., Santhamma, B., Konda, S., Venkata, P. P., Blankenship, L. M., Liu, J., Liu, Z., Altwegg, K. A., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00603-z · Cited by 40
Olcha, P., Winiarska‐Mieczan, A., Kwiecień, M., Nowakowski, Ł., Miturski, A., Semczuk, A., Kiczorowska, B., & Gałczyński, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126703 · Cited by 38
ARID1A mutations in cancer development: mechanism and therapy
Zhang, X., Zhang, Y., Zhao, J., Wu, Y., Zhang, N., & Shen, W. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad011 · Cited by 40
Costa, B. P., Nassr, M. T., Diz, F. M., Antunes, K. H., Antunes, G. L., Grün, L. K., Barbé‐Tuana, F. M., Nunes, F. B., Branchini, G., & de Oliveira, J. R. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113645 · Cited by 41
The Perspectives of Fertility Preservation in Women with Endometrial Cancer
Knez, J., Mahdawi, L. A., Takač, I., & Sobočan, M. (2021) · Cancers · doi:10.3390/cancers13040602 · Cited by 36
Guo, C., Tang, Y., Zhang, Y., & Li, G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.645388 · Cited by 36
Immune checkpoint inhibitors in endometrial cancer
Gómez-Raposo, C., Salvador, M. M., Zamora, C. A., de Santiago, B. G., & Sáenz, E. C. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103306 · Cited by 37
Rizzo, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133912 · Cited by 36
Chen, H.-Y., Cheng, W.-P., Chiang, Y., Hong, Y.-H., Ali, M. K., Huang, T., Wang, K.-L., Shieh, T., Chang, H., & Hsia, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158268 · Cited by 35
Wang, B., Wang, Y., Wang, W., Wang, Z., Zhang, Y., Pan, X. L., Wen, X., Leng, H., Guo, J. H., & Ma, X. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03120-w · Cited by 35
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
Drakes, M. L., Czerlanis, C. M., & Stiff, P. J. (2020) · Cancers · doi:10.3390/cancers12113301 · Cited by 34
SEOM-GEICO clinical guidelines on endometrial cancer (2021)
Barretina-Ginesta, M.-P., Quindós, M., Alarcón, J., Esteban, C., Gaba, L., Gómez, C., Fidalgo, J. A. P., Romero, I., Santaballa, A., & Rubio-Pérez, M. J. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02799-7 · Cited by 34
A novel strategy for tumor therapy: targeted, PAA-functionalized nano-hydroxyapatite nanomedicine
Zhang, S., Ma, X., Sha, D., Qian, J., Yuan, Y., & Liu, C. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01603a · Cited by 34
Zhang, J., Zhou, L., Xiang, J., Jin, C., Li, M., & He, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107705 · Cited by 34
Chen, H., Ma, J., Kong, F., Song, N., Wang, C., & Ma, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04707-x · Cited by 33
Li, X., Zhu, Q., Ma, M., & Guo, H. (2022) · European journal of medical research · doi:10.1186/s40001-022-00934-2 · Cited by 33
A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth
Li, S., Ou, L., Zhang, Y., Shen, F., & Chen, Y.-G. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05682-7 · Cited by 32
Liu, Q., Yu, M., & Zhang, T. (2022) · Cancers · doi:10.3390/cancers14225572 · Cited by 31
Circular RNAs: Novel biomarkers for cervical, ovarian and endometrial cancer (Review)
Shi, Y., He, R., Yu, Y., He, Y., Shao, K., Zhan, L., & Wei, B. (2020) · Oncology Reports · doi:10.3892/or.2020.7780 · Cited by 30
Zhan, L., Zhang, J., Zhang, J., Liu, X., Guo, B., Chen, J.-H., Tang, Z., Wang, W., Wang, Q.-Y., Wei, B., et al. (2023) · Biomarker Research · doi:10.1186/s40364-023-00479-4 · Cited by 29
Monk, B. J., Smith, G. B., Lima, J., Long, G. H., Alam, N., Nakamura, H., Meulendijks, D., Ghiorghiu, D. C., & Banerjee, S. N. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.12.008 · Cited by 29
An integrated autophagy-related gene signature predicts prognosis in human endometrial Cancer
Zhang, J., Wang, Z., Zhao, R., An, L., Zhou, X., Zhao, Y., & Wang, H. (2020) · BMC Cancer · doi:10.1186/s12885-020-07535-4 · Cited by 31
Shen, L., Zhang, C., Cui, K., Liang, X., Zhu, G., & Hong, L. (2023) · Adipocyte · doi:10.1080/21623945.2023.2293273 · Cited by 26
Zhang, J., An, L., 俞志誠, Zhao, R., Shi, R., Zhou, X., Wei, S., Zhang, T., Zhang, T., 冯地路, et al. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23487 · Cited by 26
Roles of estrogen receptor α in endometrial carcinoma (Review)
Ge, Y., Ni, X., Li, J., Ye, M., & Jin, X. (2023) · Oncology Letters · doi:10.3892/ol.2023.14117 · Cited by 28
Jonušienė, V., & Sasnauskienė, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_4 · Cited by 25
Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB
Cui, Y., Wu, H., Yang, L., Huang, T., Li, J., Gong, X., Li, L., Sun, X., Mao, F., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665832 · Cited by 25
Wu, Z., Jeong, J.-H., Ren, C., Yang, L., Ding, L., Li, F., Jiang, D., Zhu, Y., & Lu, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s311792 · Cited by 25
From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer
Molefi, T., Mabonga, L., Hull, R., Sebitloane, M., & Dlamini, Z. (2025) · Cancers · doi:10.3390/cancers17020320 · Cited by 24
Jiang, P., Huang, Y., Tu, Y., Li, N., Kong, W., Di, F., Jiang, S., Zhang, J., Yi, Q., & Yuan, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682925 · Cited by 24
Yuan, J., Mao, Z., Qi, L., Xu, P., Wang, C., Xu, X., Zhou, Z., Zhang, T., Yu, W., Dong, S., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.774215 · Cited by 24
Ruan, P., Wang, S., Yang, C., Huang, X., Sun, P., & Tan, A. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09751-z · Cited by 24
Xue, S., Su, L., Ke, L.-N., & Huang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1077780 · Cited by 24
Jiang, P., Wang, J., Gong, C., Yi, Q., Zhu, M., & Hu, Z. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s362166 · Cited by 23
Ribeiro-Santos, P., Vieira, C. M., Veloso, G. G. V., Giannecchini, G. V., Arenhardt, M. P., Gomes, L. M., Zanuncio, P. H. D. R., Brandão, F. S., & Nogueira‐Rodrigues, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147742 · Cited by 24
Sun, Q., Peng, Z., Li, D., Liu, X., Ding, X., & Liu, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2079256 · Cited by 23
Baiden-Amissah, R. E. M., Annibali, D., Tuyaerts, S., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13163988 · Cited by 22
Martín‐Sabroso, C., Lozza, I., Torres‐Suárez, A. I., & Fraguas‐Sánchez, A. I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101705 · Cited by 22
SWI/SNF Antagonism of PRC2 Mediates Estrogen-Induced Progesterone Receptor Expression
Wilson, M. R., Reske, J. J., Koeman, J. M., Adams, M., Joshi, N., Fazleabas, A. T., & Chandler, R. L. (2022) · Cells · doi:10.3390/cells11061000 · Cited by 22
Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers
Zhang, Y., Peng, F., & Yu, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114016 · Cited by 22
Zhang, W., Zhang, K., Ma, Y., Song, Y., Qi, T., Xiong, G., Zhang, Y., Kan, C., Zhang, J., Han, F., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115344 · Cited by 22
Kang, N., Zhang, X., Wang, Z., Dai, Y., Lu, S., Su, W., Gai, F., Zhu, C., Shen, D., & Wang, J. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155152 · Cited by 22
The Role of Hypoxia in Endometrial Cancer
Salinas-Vera, Y. M., Gallardo‐Rincón, D., Ruíz‐García, E., Silva-Cázares, M. B., de la Peña-Cruz, C. S., & López‐Camarillo, C. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210224130022 · Cited by 22
Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer
Choi, J. Y., Holowatyj, A. N., Du, M., Chen, Z., Wen, W., Schultz, N., Lipworth, L., & Guo, X. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00401 · Cited by 21
The Regulatory Role of Lipid Metabolism in Endometrial Cancer
Zhang, S., & Han, X. (2022) · Journal of Oncology · doi:10.1155/2022/6458877 · Cited by 20
Claudin‑9 is a novel prognostic biomarker for endometrial cancer
Endo, Y., Sugimoto, K., Kobayashi, M., Kobayashi, Y., Kojima, M., Furukawa, S., Soeda, S., Watanabe, T., Higashi, A. Y., Higashi, T., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5425 · Cited by 20
Pijnenborg, J. M. A., van Weelden, W. J., Reijnen, C., Xanthoulea, S., & Romano, A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00470 · Cited by 20
A novel risk score system of immune genes associated with prognosis in endometrial cancer
Zhou, H., Zhang, C., Li, H., Chen, L., & Cheng, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01317-5 · Cited by 20
Yi, H., Han, Y., & Li, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.985470 · Cited by 19
Bian, X., Sun, C., Cheng, J., & Hong, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092241 · Cited by 18
Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis
Chen, Y., Han, L., & Zheng, A. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.11.013 · Cited by 19
The Exploration of Chemokines Importance in the Pathogenesis and Development of Endometrial Cancer
Dobroch, J., Bojczuk, K., Kołakowski, A., Baczewska, M., & Knapp, P. (2022) · Molecules · doi:10.3390/molecules27072041 · Cited by 18
Meijuan, C., Xu, M. J., Fang, L., & Wang, Q. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01097-2 · Cited by 18
Cai, J., Wang, R., Chen, Y., Zhang, C., Fu, L., & Fan, C. (2023) · Genomics · doi:10.1016/j.ygeno.2023.110750 · Cited by 18
Tang, M., Yin, S., Zeng, H., Huang, A., Huang, Y., Hu, Z., Shah, A. R., Zhang, S., Li, H., & Chen, G. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06418-3 · Cited by 20
Metadata
- Authors
- Urick, M. E., & Bell, D. W.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Bell, Daphne W.
- Venue
- Nature Reviews Cancer
- Published
- 2019-08-06
- Volume
- 19
- Issue
- 9
- Pages
- 510-521
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC7446243
- OpenAlex
- W2965204233
- Cited by
- 405
- References
- 157
- Citations by year
- 2026: 19 · 2025: 57 · 2024: 58 · 2023: 70 · 2022: 101 · 2021: 66 · 2020: 32 · 2019: 2
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 HG999999)
- National Human Genome Research Institute (Z01HG200338, ZIAHG200379, ZIAHG200338)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- endometrial cancer, molecular subtyping, molecular targets, targeted therapy, early detection, risk stratification, endometrioid carcinoma, serous carcinoma, clear cell carcinoma, histological subtypes, prognosis
- MeSH terms
- Animals, Carcinoma, Female, Humans, Immunotherapy, Mutation, Prognosis, Risk, Sarcoma, Biomarkers, Tumor, Endometrial Neoplasms, Risk Assessment, Proteomics, Mice, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
